OBJECTIVE: To systematically review the clinical efficacy of Xuesaitong injection in the treatment of dyslipidemia based on Meta-analysis. METHODS: Controlled clinical trials on Xuesaitong injection in the treatment of dyslipidemia（both groups were given conventional treatment and lipid-regulating drugs

the research group was treated with Xuesaitong injection based on the control group） published from Jan. 2012 and Feb. 2022 were retrieved from CNKI

Wanfang Data

VIP

the Cochrane Library and PubMed. Quality assessment and data extraction were conducted by two researchers according to the inclusion and exclusion criteria

and Meta-analysis was performed by using Stata 15.1 software. RESULTS: A total of 11 studies（including 1 010 subjects） were enrolled. Results of Meta-analysis showed that compared with the control group

patients in the research group given Xuesaitong injection had significantly lower total cholesterol（MD=-0.59

95%CI=-0.83--0.34

P<0.05）

triacylglycerol（MD=-0.52

95%CI=-0.80--0.24

P<0.05）

low density lipoprotein cholesterin（MD=-0.30

95%CI=-0.48--0.11

P<0.05） levels and significantly higher high density lipoprotein cholesterin（MD=0.24

95%CI=0.14-0.34

P<0.05）

with statistically significant differences. No adverse drug reactions related to Xuesaitong injection were mentioned in the involved studies. CONCLUSIONS: The application of Xuesaitong injection on patients with dyslipidemia can effectively regulate blood lipid levels

without any significant adverse drug reactions.